Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function

Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Isabel, Templeton, Megan L., Lo, Yun, Rajan, Anusha, Stull, Sylvia M., Garrison, Sarah M., Salter, Alexander I., Smythe, Kimberly S., Correnti, Colin E., Srivastava, Shivani, Yeung, Cecilia C. S., Riddell, Stanley R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275707/
https://www.ncbi.nlm.nih.gov/pubmed/36469024
http://dx.doi.org/10.1182/bloodadvances.2022008559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275707/
https://www.ncbi.nlm.nih.gov/pubmed/36469024
http://dx.doi.org/10.1182/bloodadvances.2022008559

Ejemplares similares